News

News

Hikma and Sun Pharma enter into exclusive licensing agreement for ILUMYA™ for the Middle East and North Africa region

News

News

Hikma launches a generic version of Afinitor® Tablets, 2.5mg, 5mg, 7.5mg

Update

Update

Hikma update regarding COVID-19

Our impact

Every day, our medicines are used by approximately 13 million people. The impact we have on people's lives is important, positive and far-reaching.

Case study

Case study

Our support and impact for the Healthy Kitchen Project

Case study

Case study

Our support and impact; improving patient’s access to ritonavir

Insight

Insight

Two ways to minimise the impact of COVID-19 on vulnerable communities

News

News

Hikma responds to COVID-19 shortage with launch of Propofol Injectable Emulsion, USP

Find out more

Who we are. We make high quality medicines and make them accessible to the people that need them.

Corporate social responsibility

Corporate social responsibility

Hikma launches employee matching donation campaign to support local US food banks and pantries

Find out more

Find out more

Our commitment to sustainability

Find out more

Find out more

We develop, manufacture and market nearly 700 quality branded and non-branded generic medicines worldwide.